The fibrinolysis system: Regulation of activity and physiologic functions of its main components

被引：69

作者：

Dobrovolsky, AB ^{[1
]}

Titaeva, EV ^{[1
]}

机构：

[1] Cardiol Res Ctr, Moscow 121552, Russia

来源：

BIOCHEMISTRY-MOSCOW | 2002年 / 67卷 / 01期

关键词：

plasminogen activators; inhibitors of fibrinolysis; thrombosis; risk factors; cardiovascular diseases;

D O I：

10.1023/A:1013960416302

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

This review summarizes basic properties and mechanisms of activation and inhibition of main components of the fibrinolytic system that, acting in accord with the system of blood coagulation, provides temporal formation of fibrin clots at sites of vascular injury for the time required for the regeneration of vascular wall. Impairments in the fibrinolytic system may cause bleedings or thrombotic complications in patients. The predictive value of some components of the fibrinolytic system with respect to the development of complications of atherothrombosis is considered.

引用

页码：99 / 108

页数：10

共 75 条

[1] Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma - A potential mechanism of lesion stabilization [J].

Aikawa, M ;

Rabkin, E ;

Okada, Y ;

Voglic, SJ ;

Clinton, SK ;

Brinckerhoff, CE ;

Sukhova, GK ;

Libby, P .

CIRCULATION, 1998, 97 (24) :2433-2444

[2] COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS [J].

ALTMAN, R ;

CARRERAS, L ;

DIAZ, R ;

FIGUEROA, E ;

PAOLASSO, E ;

PARODI, JC ;

CADE, JF ;

DONNAN, G ;

EADIE, MJ ;

GAVAGHAN, TP ;

OSULLIVAN, EF ;

PARKIN, D ;

RENNY, JTG ;

SILAGY, C ;

VINAZZER, H ;

ZEKERT, F ;

ADRIAENSEN, H ;

BERTRANDHARDY, JM ;

BRAN, M ;

DAVID, JL ;

DRICOT, J ;

LAVENNEPARDONGE, E ;

LIMET, R ;

LOWENTHAL, A ;

MORIAU, M ;

SCHAPIRA, S ;

SMETS, P ;

SYMOENS, J ;

VERHAEGHE, R ;

VERSTRAETE, M ;

ATALLAH, A ;

BARNETT, H ;

BATISTA, R ;

BLAKELY, J ;

CAIRNS, JA ;

COTE, R ;

CROUCH, J ;

EVANS, G ;

FINDLAY, JM ;

GENT, M ;

LANGLOIS, Y ;

LECLERC, J ;

NORRIS, J ;

PINEO, GF ;

POWERS, PJ ;

ROBERTS, R ;

SCHWARTZ, L ;

SICURELLA, J ;

TAYLOR, W ;

THEROUX, P .

BMJ-BRITISH MEDICAL JOURNAL, 1994, 308 (6921) :81-100

[3]

BACHMANN F, 1987, THROMB DIATH HAEMO, P227

[4]

Badimon JJ, 1999, THROMB HAEMOSTASIS, V82, P997

[5] TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex [J].

Bajzar, L ;

Morser, J ;

Nesheim, M .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (28) :16603-16608

[6] Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway [J].

Bajzar, L .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2000, 20 (12) :2511-2518

[7] The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent [J].

Bajzar, L ;

Nesheim, ME ;

Tracy, PB .

BLOOD, 1996, 88 (06) :2093-2100

[8] DIFFERENT N-TERMINAL FORMS OF ALPHA-2-PLASMIN INHIBITOR IN HUMAN PLASMA [J].

BANGERT, K ;

JOHNSEN, AH ;

CHRISTENSEN, U ;

THORSEN, S .

BIOCHEMICAL JOURNAL, 1993, 291 :623-625

[9]

Blasi F, 1999, THROMB HAEMOSTASIS, V82, P298

[10] Plasma and recombinant thrombin-activable fibrinolysis inhibitor (TAFI) and activated TAFI compared with respect to glycosylation, thrombin/thrombomodulin-dependent activation, thermal stability, and enzymatic properties [J].

Boffa, MB ;

Wang, W ;

Bajzar, L ;

Nesheim, ME .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (04) :2127-2135

← 1 2 3 4 5 6 7 8 →